ESR1 and breast cancer: The high prevalence of PI3K activation in tumors has led to the development of PI3K inhibitors, with recent regulatory approval for two PI3K inhibitors in estrogen receptor positive (ER+ve) breast cancer (André et al., 2019; Di Leo et al., 2018; Janku et al., 2018).